Remove Branding Remove Generic Drugs Remove Medicine Remove Pharma Companies
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. Then there is the cost of generic drugs. bil­lion in 2020 if it had pur­chased 77 of 89 drugs from Cuban’s firm.

Pharmacy 227
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

anti-kickback law that the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford the medicine that costs $225,000 annually. Pharma companies have very little control over patients’ prices for their Rxs. A federal appeals court rejected Pfizer’s challenge to a U.S.

Pharmacy 226
article thumbnail

Common sense approach to the pharma industry

World of DTC Marketing

Pharma companies are still too focused on profits while people continue to rely on prescription drugs to compensate for unhealthy lifestyles. The headline and byline in a Times editorial said it all “Don’t Fall for Big Pharma’s Savior Act, Heroic work went into the development of the coronavirus vaccines.

article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent from 2018.

In-Vivo 187
article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost.

article thumbnail

India: Why is the country ramping up drug discovery research?

Drug Discovery World

According to a report by Deloitte, globally India is the third largest in the world by volume and 11th by value, comprising over 3,000 pharma companies and 10,500 manufacturing facilities 2. Similarly, The Times of India says that branded generic medicines have “long fuelled India’s pharmaceutical exports” 4.